Marekani - Kiingereza - NLM (National Library of Medicine)

ethicon, inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k), human thrombin (unii: 6k15abl77g) (human thrombin - unii:6k15abl77g) - fibrinogen human 8.6 mg in 1 cm2 - evarrest® is a fibrin sealant patch indicated for use with manual compression as an adjunct to hemostasis in adult patients undergoing surgery, when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. limitations for use: - cannot safely or effectively be used in place of sutures or other forms of mechanical ligation in the treatment of major arterial or venous bleeding. - not for use in children under one month of age - laparoscopic and other minimally invasive surgeries where manual compression would be difficult to achieve. do not use evarrest® for - bleeding from large defects in visible arteries or veins where the injured vascular wall requires conventional surgical repair and maintenance of vessel patency or where there would be persistent exposure of evarrest to blood flow and/or pressure during absorption of the product. - intravascular application. this can result in life-threatening thromboembolic events. - individuals know

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in minor surgery, and as a prophylaxis in patients with haemophilia b. it has not been evaluated in major surgery. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels fo these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors. indications as at 14 may 1999: monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment factor ii, vii or x deficiencies because is does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Malta - Kiingereza - Medicines Authority

bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 430 iu - antihemorrhagics

Malta - Kiingereza - Medicines Authority

bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 500 iu von willebrand factor, human 860 iu - antihemorrhagics

Malta - Kiingereza - Medicines Authority

bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 1000 iu von willebrand factor, human 1720 iu - antihemorrhagics

Israeli - Kiingereza - Ministry of Health

csl behring ltd., israel - human fibrinogen - powder for solution for inj/inf - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human fibrinogen; human thrombin; calcium chloride; aprotinin - solution for sealant - 4 ml - local hemostatics; tissue adhesives

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - human fibrinogen; human thrombin; calcium chloride; aprotinin - solution for sealant - 4 ml - local hemostatics; tissue adhesives